FINAL YEAR B.PHARM. SEMESTER-VII (2011 COURSE) :
SUMMER - 2018
SUBJECT: CLINICAL PHARMACY

Day : **Friday** Time: **02.00 PM TO 05.00 PM**
Date : **04/05/2018** **S-2018-3980** Max. Marks: 80

N.B.:

1) **Q.No.1** and **Q. No.5** are **COMPULSORY**. Out of the remaining questions attempt **ANY TWO** questions from each section.
2) Answers to both the sections should be written in **SEPARATE** answer books.
3) Figures to the right indicate **FULL** marks.

SECTION – I

Q.1 Answer **ANY FIVE** of the following: **[10]**

a) What are components of Drug Therapy Monitoring?
b) Expand following abbreviations PCV and CK.
c) Give the significance of Serum Creatinine.
d) Define hypokalemia.
e) Define Minimum Inhibitory Concentration (MIC).
f) Give significance of Thyroid Stimulating Hormone (TSH).
g) Define drug information service.

Q.2 **a)** Discuss systematic approach for solving drug information query. **[08]**
b) Classify different adverse drug reactions. **[07]**

Q.3 **a)** Discuss thyroid function tests. **[08]**
b) Explain Drug Utilization Evaluation Cycle. **[07]**

Q.4 Write note on **ANY THREE** of the following: **[15]**

a) Ward round participation
b) Medication history
c) Hyponatremia
d) Quality assurance of clinical pharmacy services

SECTION – II

Q.5 Answer **ANY FIVE** of the following: **[10]**

a) What is Phase – II clinical trial?
b) What is the need for poison information services?
c) Give importance of approval of a drug.
d) What is the aim of Pharmacovigilance?
e) Define clinical trial.
f) What are the requirements for setting Drug Information Centre?
g) Explain in brief any one mechanism of Adverse Drug Reaction (ADR).

Q.6 **a)** Discuss critical evaluation of drug information and literature. **[08]**
b) Discuss preparation of verbal and written Drug Information Reports. **[07]**

Q.7 **a)** Explain organization and resources of Poison Information (PI) services. **[08]**
b) Discuss role of Pharmacist in management of Adverse Drug Reactions (ADRs). **[07]**

Q.8 Write note on **ANY THREE** of the following: **[15]**

a) Good Clinical Practices (GCP)
b) Phase 'O' trial
c) Predisposing factors for Adverse Drug Reactions (ADRs)
d) Role of Pharmacist in clinical trial

* * * *